Literature DB >> 19339244

FRS2 via fibroblast growth factor receptor 1 is required for platelet-derived growth factor receptor beta-mediated regulation of vascular smooth muscle marker gene expression.

Pei-Yu Chen1, Michael Simons, Robert Friesel.   

Abstract

Vascular smooth muscle cells (VSMC) exhibit phenotypic plasticity and change from a quiescent contractile phenotype to a proliferative synthetic phenotype during physiological arteriogenesis and pathological conditions such as atherosclerosis and restenosis. Platelet-derived growth factor (PDGF)-BB is a potent inducer of the VSMC synthetic phenotype; however, much less is known about the role of fibroblast growth factor-2 (FGF2) in this process. Here, we show using signal transduction mutants of FGF receptor 1 (FGFR1) expressed in rat VSMC that the adaptor protein FRS2 is essential for FGFR1-mediated phenotypic modulation and down-regulation of VSMC smooth muscle alpha-actin (SMA) gene expression. In addition, we show that PDGF-BB and FGF2 act synergistically to induce cell proliferation and down-regulate SMA and SM22alpha in VSMC. Furthermore, we show that PDGF-BB induces tyrosine phosphorylation of FGFR1 and that this phosphorylation is mediated by PDGF receptor-beta (PDGFRbeta), but not c-Src. We demonstrate that FRS2 co-immunoprecipitates with PDGFRbeta in a complex that requires FGFR1 and that both the extracellular and the intracellular domains of FGFR1 are required for association with PDGFRbeta, whereas the cytoplasmic domain of FGFR1 is required for FRS2 association with the FGFR1-PDGFRbeta complex. Knockdown of FRS2 in VSMC by RNA interference inhibited PDGF-BB-mediated down-regulation of SMA and SM22alpha without affecting PDGF-BB mediated cell proliferation or ERK activation. Together, these data support the notion that PDGFRbeta down-regulates SMA and SM22alpha through formation of a complex that requires FGFR1 and FRS2 and prove novel insight into VSMC phenotypic plasticity.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19339244      PMCID: PMC2708892          DOI: 10.1074/jbc.M809399200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  36 in total

1.  Proliferation of smooth muscle cells after vascular injury is inhibited by an antibody against basic fibroblast growth factor.

Authors:  V Lindner; M A Reidy
Journal:  Proc Natl Acad Sci U S A       Date:  1991-05-01       Impact factor: 11.205

2.  FGFR1 forms an FRS2-dependent complex with mTOR to regulate smooth muscle marker gene expression.

Authors:  Pei-Yu Chen; Robert Friesel
Journal:  Biochem Biophys Res Commun       Date:  2009-03-13       Impact factor: 3.575

3.  Distinct patterns of expression of fibroblast growth factors and their receptors in human atheroma and nonatherosclerotic arteries. Association of acidic FGF with plaque microvessels and macrophages.

Authors:  E Brogi; J A Winkles; R Underwood; S K Clinton; G F Alberts; P Libby
Journal:  J Clin Invest       Date:  1993-11       Impact factor: 14.808

4.  Role of basic fibroblast growth factor and platelet-derived growth factor (B-chain) in neointima formation after arterial injury.

Authors:  V Lindner
Journal:  Z Kardiol       Date:  1995

5.  Expression of basic fibroblast growth factor and its receptor by smooth muscle cells and endothelium in injured rat arteries. An en face study.

Authors:  V Lindner; M A Reidy
Journal:  Circ Res       Date:  1993-09       Impact factor: 17.367

6.  Platelet-derived growth factor-BB-induced suppression of smooth muscle cell differentiation.

Authors:  B J Holycross; R S Blank; M M Thompson; M J Peach; G K Owens
Journal:  Circ Res       Date:  1992-12       Impact factor: 17.367

7.  Fibroblast growth factor receptors have different signaling and mitogenic potentials.

Authors:  J K Wang; G Gao; M Goldfarb
Journal:  Mol Cell Biol       Date:  1994-01       Impact factor: 4.272

8.  Platelet-derived growth factor stimulates growth factor receptor binding protein-2 association with Shc in vascular smooth muscle cells.

Authors:  C W Benjamin; D A Jones
Journal:  J Biol Chem       Date:  1994-12-09       Impact factor: 5.157

9.  Signal transduction by fibroblast growth factor receptor-4 (FGFR-4). Comparison with FGFR-1.

Authors:  S Vainikka; V Joukov; S Wennström; M Bergman; P G Pelicci; K Alitalo
Journal:  J Biol Chem       Date:  1994-07-15       Impact factor: 5.157

10.  Ligand-independent activation of fibroblast growth factor receptors by point mutations in the extracellular, transmembrane, and kinase domains.

Authors:  K M Neilson; R Friesel
Journal:  J Biol Chem       Date:  1996-10-04       Impact factor: 5.157

View more
  25 in total

1.  The FGF-2-derived peptide FREG inhibits melanoma growth in vitro and in vivo.

Authors:  Maria S Aguzzi; Debora Faraone; Daniela D'Arcangelo; Francesco De Marchis; Gabriele Toietta; Domenico Ribatti; Alberto Parazzoli; Paolo Colombo; Maurizio C Capogrossi; Antonio Facchiano
Journal:  Mol Ther       Date:  2010-10-05       Impact factor: 11.454

Review 2.  An overview of potential molecular mechanisms involved in VSMC phenotypic modulation.

Authors:  Ming-Jie Zhang; Yi Zhou; Lei Chen; Yan-Qin Wang; Xu Wang; Yan Pi; Chang-Yue Gao; Jing-Cheng Li; Li-Li Zhang
Journal:  Histochem Cell Biol       Date:  2015-12-26       Impact factor: 4.304

3.  Deficiency of Sef is associated with increased postnatal cortical bone mass by regulating Runx2 activity.

Authors:  Qing He; Xuehui Yang; Yan Gong; Dmitry Kovalenko; Ernesto Canalis; Clifford J Rosen; Robert E Friesel
Journal:  J Bone Miner Res       Date:  2014       Impact factor: 6.741

Review 4.  PDGF: the nuts and bolts of signalling toolbox.

Authors:  Ammad Ahmad Farooqi; Salman Waseem; Asma M Riaz; Bilal Ahmed Dilawar; Shahzeray Mukhtar; Sehrish Minhaj; Makhdoom Saad Waseem; Suneel Daniel; Beenish Ali Malik; Ali Nawaz; Shahzad Bhatti
Journal:  Tumour Biol       Date:  2011-07-19

Review 5.  Novel tyrosine kinase signaling pathways: implications in vascular remodeling.

Authors:  Sri N Batchu; Vyacheslav A Korshunov
Journal:  Curr Opin Nephrol Hypertens       Date:  2012-03       Impact factor: 2.894

6.  Association of FGF-2 Concentrations with Atheroma Progression in Chronic Kidney Disease Patients.

Authors:  Milica Bozic; Angels Betriu; Marcelino Bermudez-Lopez; Alberto Ortiz; Elvira Fernandez; Jose M Valdivielso
Journal:  Clin J Am Soc Nephrol       Date:  2018-03-08       Impact factor: 8.237

7.  Myristoylation-Dependent Palmitoylation of the Receptor Tyrosine Kinase Adaptor FRS2α.

Authors:  Barbara Barylko; Yu-Ju Chen; Jared Hennen; Isaac Angert; Yan Chen; Joachim D Mueller; Hui-Qiao Sun; Clinton A Taylor; Jen Liou; Helen Yin; Joseph P Albanesi
Journal:  Biochemistry       Date:  2019-06-11       Impact factor: 3.162

8.  The microvascular niche instructs T cells in large vessel vasculitis via the VEGF-Jagged1-Notch pathway.

Authors:  Zhenke Wen; Yi Shen; Gerald Berry; Farhad Shahram; Yinyin Li; Ryu Watanabe; Yaping Joyce Liao; Jörg J Goronzy; Cornelia M Weyand
Journal:  Sci Transl Med       Date:  2017-07-19       Impact factor: 17.956

9.  Porcine colonization of the Americas: a 60k SNP story.

Authors:  W Burgos-Paz; C A Souza; H J Megens; Y Ramayo-Caldas; M Melo; C Lemús-Flores; E Caal; H W Soto; R Martínez; L A Alvarez; L Aguirre; V Iñiguez; M A Revidatti; O R Martínez-López; S Llambi; A Esteve-Codina; M C Rodríguez; R P M A Crooijmans; S R Paiva; L B Schook; M A M Groenen; M Pérez-Enciso
Journal:  Heredity (Edinb)       Date:  2012-12-19       Impact factor: 3.821

10.  FGF regulates TGF-β signaling and endothelial-to-mesenchymal transition via control of let-7 miRNA expression.

Authors:  Pei-Yu Chen; Lingfeng Qin; Carmen Barnes; Klaus Charisse; Tai Yi; Xinbo Zhang; Rahmat Ali; Pedro P Medina; Jun Yu; Frank J Slack; Daniel G Anderson; Victor Kotelianski; Fen Wang; George Tellides; Michael Simons
Journal:  Cell Rep       Date:  2012-11-29       Impact factor: 9.423

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.